Shaun Phillip Jackson
 | The topic of this article may not meet Wikitia's general notability guideline. |
Shaun Phillip Jackson | |
|---|---|
| Add a Photo | |
| Born | Australia |
| Citizenship | Australian |
| Alma mater | Monash University |
| Occupation | Clinician-scientist and Academic |
| Known for | Research on Stroke, Thrombosis & Red Blood Cells |
Notable work | Cardiology, Vascular Biology |
Shaun Phillip Jackson is an Australian clinician-scientist and academic known for his research in cardiology and vascular biology.
In 2004, together with Hatem Salem, he established the Australian Centre for Blood Diseases at the Alfred Medical Research and Education Precinct, focusing on blood cancers and the mechanisms of haemostasis and thrombosis. He was awarded an NHMRC Australia Fellowship in 2010 and, in 2013, became the inaugural Director of Cardiovascular Research at the Heart Research Institute and Charles Perkins Centre, University of Sydney, a role he held until 2023.
In 2025, Jackson published findings in "Nature (journal)" identifying red blood cells as a key factor in organ damage associated with Covid-19, heart attack, and stroke.
Early Life and education
Professor Shaun Phillip Jackson is an Australian clinician-scientist and academic known for his research in cardiology and vascular biology.
Jackson studied at Monash University, Melbourne, obtaining an MBBS (Bachelor of Medicine, Bachelor of Surgery) in Medicine with First Class Honours in 1989 and a Ph.D. in Medicine in 1995.
In 1995, he received the Inaugural Victorian Premier's Award for Excellence in Medical Research for his project on Thrombosis.[1]
Career and research
Jackson has been an NHMRC Research Fellow for the last 28 years and is currently recognised as a Senior Principal Research Fellow.
In 1995, Jackson began his career with employment at Monash University as a post-doctoral researcher.
In 1996, he received the R. Douglas Wright fellowship through the National Health and Medical Research Council, establishing an independent research laboratory at Monash University in 1998.
During this time, his research on Thrombosis discovered the possibility of creating a drug that inhibited (blocked) the function of the PI3 Kinase. With the research being deemed commercially viable, in collaboration with Professor Hatem Salem, Jackson co-founded the biotechnology company Kinacia.[2][3]
Here, the laboratory identified that PI 3-kinase p110 was essential for arterial thrombus formation. This seminal discovery provided new insights into the molecular mechanisms of arterial thrombus formation.[4] Jackson and his team secured $15m in venture capital to develop two new classes of PI 3-kinase inhibitors. They conducted the first-ever Phase I human clinical study on PI 3-kinase inhibitors and collaborated with AstraZeneca in the Phase I clinical study of AZD6482, the antithrombotic PI 3-kinase inhibitor. Following these advancements, AstraZeneca acquired the inhibitors for further clinical development.
In 2004, Professor Shaun Jackson and Professor Hatem Salem established the Australian Centre for Blood Diseases (ACBD) within The Alfred Hospital Medical Research and Education Precinct.
During the mid 2000's, Jackson became a faculty member at the Scripps Research Institute in La Jolla, San Diego (California, USA).[5]. was awarded an National Health and Medical Research Council Australia Fellowship.[6] [7] and was appointed the Inaugural Director of Cardiovascular Research, the Heart Research Institute (HRI) & Charles Perkins Centre(CPC), University of Sydney, where he remained until 2023.[8] He later received an honorary appointment at the Department, Haematology, Cambridge University.[9]
In 2020, Professor Jackson’s research team discovered a new pathway triggering the formation of blood clots. They were able to demonstrate that biomechanical forces (disturbances in blood flow) can activate clotting cells, leading to further growth.[10][11]
In early 2024, Jackson’s contract with the Heart Research Institute came to an end. A legal case was filed in the Federal Court involving both Jackson and the Institute, with each party presenting differing accounts relating to the nature of his exit and other internal concerns. The investigation is still before the court.[12]
In 2025, Jackson’s research into ischaemic endothelial necroptosis marked a breakthrough in vascular biology, offering new insight into the mechanisms behind organ damage.[13][14] [15]
Published in "Nature (journal)". The study revealed that red blood cells, rather than traditional blood clots, are the hidden cause to organ damage in severe Covid-19, heart attack and stroke patients.[16]
Honours and Awards
- Honorary visiting fellow, Cambridge University. - 2019[17]
- NSW Ministerial Award for Cardiovascular Research Excellence - 2018[18]
- Investigator Recognition Award & Medal, Awarded by the International Society on Thrombosis and Haemostasis - 2011[19]
- Australia Fellowship, NHMRC - 2010
- Marion Barnhart Prize, Awarded by the International Society on Thrombosis and Haemostasis - 2009
- AMREP Research Prize - 2006
- AMGEN National Medical Researcher Award - 2005
- Rudolph Virchow Medal for Outstanding Contributions to Thrombosis Research - 2004[20]
- Tall Poppy Award, Australian Institute of Political Science - 1999
- Inaugural Premier's Award for Excellence in Medical Research - 1995
Bibliography
Selected Publications
- 2025, Ischaemic endothelial necroptosis induces haemolysis and COVID-19 angiopathy, "Nature (journal)"
- 2019, An integrin αIIbβ3 intermediate affinity state mediates biomechanical platelet aggregation,Nature Materials
- 2018, Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets,Nature Communications
- 2017, Endogenous fibrinolysis facilitates clot retraction in vivo, Ash Publications.
- 2009, Phosphoinositide 3-Kinase p110β Regulates Integrin αIIbβ3 Avidity and the Cellular Transmission of Contractile bForces*, “Journal of Biological Chemistry”
- 2009, A shear gradient–dependent platelet aggregation mechanism drives thrombus formation,Nature Medicine
- 2005, Importance of Temporal Flow Gradients and Integrin αIIbβ3 Mechanotransduction for Shear Activation of Platelets, “Journal of Biological Chemistry”
- 2005, PI 3-kinase p110β: a new target for antithrombotic therapy,Nature Medicine
- 2003, Intercellular calcium communication regulates platelet aggregation and thrombus growth, “Journal of Cell Biology”
- 2002, Essential role for phosphoinositide 3-kinase in shear-dependent signalling between platelet glycoprotein Ib/V/IX and integrin αIIbβ3, Ash Publications
References
- ↑ https://vgls.sdp.sirsidynix.net.au/client/search/asset/1296963
- ↑ Burshtein, Sam; Cebon, Peter (2024). Commercialising university research: The case of Kinacia Pty Ltd. Swinburne. doi:10.25916/sut.26286157.v1. ISBN 978-0-9803328-3-4.
- ↑ "Kinacia". Measured success. MUP academic monograph series. Melbourne University Press. 2008. pp. 166–182. ISBN 978-0-522-85570-8.
- ↑ Jackson, Shaun P.; Schoenwaelder, Simone M.; Goncalves, Isaac; Nesbitt, Warwick S.; Yap, Cindy L.; Wright, Christine E.; Kenche, Vijaya; Anderson, Karen E.; Dopheide, Sacha M.; Yuan, Yuping; Sturgeon, Sharelle A.; Prabaharan, Hishani; Thompson, Philip E.; Smith, Gregg D.; Shepherd, Peter R.; Daniele, Nathalie; Kulkarni, Suhasini; Abbott, Belinda; Saylik, Dilek; Jones, Catherine; Lu, Lucy; Giuliano, Simon; Hughan, Sascha C.; Angus, James A.; Robertson, Alan D.; Salem, Hatem H. (2005). "PI 3-kinase p110β: A new target for antithrombotic therapy". Nature Medicine. 11 (5): 507–514. doi:10.1038/nm1232.
- ↑ "Faculty | Scripps Research".
- ↑ "HRI awarded three prestigious NHMRC grants".
- ↑ "NHMRC project grants support vital research". 24 October 2013.
- ↑ "New prothrombotic mechanism linking diabetes to cardiovascular disease".
- ↑ "HRI Director of Cardiovascular Research in the UK • HRI".
- ↑ "New prothrombotic mechanism linking diabetes to cardiovascular disease".
- ↑ "Blood clot breakthrough for diabetics • HRI".
- ↑ "Heart Research Institute fights claim it ousted whistle-blower". 9 July 2024.
- ↑ "Breakthrough discovery links organ failure to long Covid". The Australian.
- ↑ "How Covid Can Break Blood Vessels and Clog Arteries". Bloomberg News.
- ↑ "Sydney Scientists: World First Discovery Reveals the Hidden Cause of Organ Damage in COVID-19 and Other Deadly Conditions". 5 June 2025.
- ↑ Wu, Mike C. L.; Italiano, Ethan; Jarvis-Child, Rocko; Alwis, Imala; Smythe, Rhyll; Albornoz, Eduardo A.; Noonan, Jonathan; Portelli, Marie; Baptista, Marissa; MacLean, Jessica; Noori, Pashtana; Yang, Jinglu; Lee, John D.; McFadyen, James D.; Sharland, Alexandra F.; Woodruff, Trent M.; Samson, Andre L.; Rapkiewicz, Amy; Barrett, Tessa J.; Pham, Alan; Schoenwaelder, Simone M.; Yuan, Yuping; Jackson, Shaun P. (2025). "Ischaemic endothelial necroptosis induces haemolysis and COVID-19 angiopathy". Nature. 643 (8070): 182–191. Bibcode:2025Natur.643..182W. doi:10.1038/s41586-025-09076-x.
- ↑ "HRI Director of Cardiovascular Research in the UK • HRI".
- ↑ "News | HRI Receives Research Award • Heart Research Institute".
- ↑ "Blood-clotting work recognised". 7 September 2011.
- ↑ https://www.monash.edu/__data/assets/pdf_file/0012/979536/med-acbd-resrep-txt-4-7-05.pdf
External links
This article "Shaun Phillip Jackson" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.